Amicus Therapeutics
FOLD
C$8.41
Share price
0.99%
Change (1 day)
-39.98%
Change (1 year)
Categories
Revenue for Amicus Therapeutics (FOLD)
Revenue in 2025 (TTM): C$0.75 Billion
According to Amicus Therapeutics
's latest financial reports the company's current revenue (TTM 
) is C$0.74 Billion. In 2024 the company made a revenue of C$0.75 Billion an increase over the revenue in the year 2023 that were of C$0.52 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Amicus Therapeutics from 2008 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | C$0.75 B | 0.21% |
| 2024 | C$0.75 B | 43.12% |
| 2023 | C$0.52 B | 18.56% |
| 2022 | C$0.44 B | 14.74% |
| 2021 | C$0.38 B | 17.05% |
| 2020 | C$0.33 B | 39.76% |
| 2019 | C$0.23 B | 91.49% |
| 2018 | C$0.12 B | 167.7% |
| 2017 | C$46.43 M | 596.86% |
| 2016 | C$6.66 M | |
| 2015 | N/A | -100% |
| 2014 | C$1.42 M | 267.59% |
| 2013 | C$0.38 M | -97.89% |
| 2012 | C$18.3 M | -16.03% |
| 2011 | C$21.8 M | 2265.66% |
| 2010 | C$0.92 M | -98.64% |
| 2009 | C$67.71 M | 272.15% |
| 2008 | C$18.19 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Biogen BIIB | C$13.48 B | 1,707.34% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | C$4.05 B | 443.18% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | C$0.35 B | -52.21% | 🇺🇸 USA |
 GlaxoSmithKline GSK | C$55.75 B | 7,372.57% | 🇬🇧 UK |
 Lexicon Pharmaceuticals
LXRX | C$42.87 M | -94.25% | 🇺🇸 USA |
 Novo Nordisk NVO | C$60.07 B | 7,951.38% | 🇩🇰 Denmark |